H.C. Wainwright analyst Emily Bodnar has maintained their neutral stance on AGEN stock, giving a Hold rating yesterday.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Emily Bodnar’s rating is based on a combination of factors surrounding Agenus’s ongoing regulatory interactions and clinical trial developments. The company is in the process of re-engaging with the FDA for its bot/bal treatment in metastatic colorectal cancer, following previous advice to conduct a Phase 3 trial. Recent FDA changes and additional follow-up data from earlier trials have prompted Agenus to seek a potentially faster approval pathway.
While the company has shown promising efficacy and safety data in its trials, the need for further updates on the regulatory path and the FDA’s stance remains crucial. Agenus is also exploring Phase 3 trial designs and has engaged new leadership to bolster its regulatory efforts. Until more clarity is provided on these fronts, Emily Bodnar maintains a Neutral stance on the stock, reflecting a cautious approach to the company’s near-term prospects.
Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Femasys, and Agenus. According to TipRanks, Bodnar has an average return of -9.4% and a 27.44% success rate on recommended stocks.